NewsFlash »

Facet Biotech Enrolls First Patient In Elotuzumab Phase 2 Myeloma Study – Facet Biotech an­nounced the first patient’s en­roll­ment in a Phase 2 study of elotuzumab, which is cur­rently being in­ves­ti­gated for the treat­ment of re­lapsed mul­ti­ple myeloma. Up to 60 patients will be recruited to re­ceive either 10 mg/kg or 20 mg/kg of elotuzumab in com­bi­na­tion with Revlimid (lena­lido­mide) and low-dose dexamethasone (Decadron). In the Phase 1 trial, 92 per­cent of patients who com­pleted at least two treat­ment cycles achieved at least partial re­sponse (see re­lated Beacon news). For more in­for­ma­tion, please see the Facet Biotech press re­lease and the clinical trial description.

Phase 1 Study Of BioInvent’s Drug Candidate BI-505 Treats First Myeloma Patient – BioInvent an­nounced treat­ment of the first patient with BI-505 in a Phase 1 study eval­u­ating the drug for the treat­ment of ad­vanced mul­ti­ple myeloma. The study is recruiting 30 to 40 patients to re­ceive BI-505 in­tra­venously every sec­ond week for four weeks or longer. Re­searchers will eval­u­ate the drug’s safety, ac­­tiv­ity, and dosage limits. For more in­for­ma­tion, please see the BioInvent press re­lease and the clinical trial description.

LLS Seminar: Understanding Lab & Radiology Tests – On Jan­u­ary 25, the Leukemia & Lymphoma Society (LLS) is holding an in­for­ma­tional seminar on how to read and under­stand med­i­cal re­­sults, in­clud­ing CT scans, PETs, MRIs, and blood tests. The event will take place at the Katz Cancer Resource Center in Santa Cruz, CA from 11:30 a.m. to 12:30 p.m. For more in­for­ma­tion or to register, please visit the LLS Web site.

LLS Event: Living With Myeloma – On Jan­u­ary 25, the Leukemia & Lymphoma Society (LLS) will host a free pro­gram on mul­ti­ple myeloma from 5 p.m. to 6:30 p.m. at the Moffit Cancer Center in Tampa, FL. Dr. Melissa Alsina will give an overview of myeloma and cover the fol­low­ing topics: the latest in drug ther­a­pies, dis­ease and treat­ment side effects, emotional repercussions and sup­port resources, and clin­i­cal trial op­tions. A question and answer session and com­pli­mentary dinner will be in­cluded. Pre-registration is re­quired. For more in­for­ma­tion or to register, please visit the LLS Web site.

For a more detailed listing of myeloma re­lated events, please check the Myeloma Beacon Events Calendar.